Background: Cognitive impairment among older HIV+ individuals could be due to HIV itself, vascular disease, or the early onset of Alzheimer’s disease. Amyloid deposition, a hallmark of Alzheimer’s, can be detected by brain position emission tomography (PET) imaging. A previous PET study using another marker of amyloid, [11C] Pittsburgh B compound (PIB), in 16 HIV+ subjects (age: mean(SD) =46(3) years) with normal cognition (69%) and HIV-associated neurocognitive disorder (HAND) (31%) did not show increased [11C] PIB uptake. The objective of this study was to determine whether abnormal amyloid deposits measured by PET [18F] AV-45 is present in older HIV+ individuals > age 50 years, and is increased in HIV+ individuals with symptomatic HAND (mild neurocognitive disorder (MND) and dementia), compared to asymptomatic HAND [asymptomatic neurocognitive impairment (ANI)] and normal cognition).
Methods: 25 HIV+ individuals (age: mean(SD) = 60.8(6.0) years) received neurological evaluations including neuropsychological testing, functional assessments and high resolution research tomography (HRRT) PET [18F] AV-45 imaging. 6 HIV- individuals [age: mean(SD) = 68.3(7.8)] received similar assessments. AV-45 uptake was measured by cerebellum standardized uptake value ratios (SUVR) in 17 cortical and subcortical regions, and compared 1) between HIV+ individuals with and without symptomatic HAND, and 2) by HIV serostatus using the Wilcoxon test. Qualitative analysis of an abnormal PET scan was also performed.
Results: HAND stage for HIV+ individuals was as follows: normal cognition-3, ANI-8, MND-7, HIV dementia-6. 12% of the HIV+ individuals (age range 57-64 years) had increased AV-45 uptake by qualitative analysis. HIV+ individuals with symptomatic HAND (MND and dementia) had increased AV-45 uptake in the hippocampus [median(IQR)= 1.26(1.10-1.35)] and basal ganglia [median(IQR)= 1.64 (1.39-1.76)], compared to HIV+ individuals with ANI/normal cognition [hippocampus median(IQR) = 1.07(1.03-1.16)], (p= 0.049) and basal ganglia [median(IQR) =1.49(1.41-1.52), (p= 0.049). There were no differences in regional uptake by HIV serostatus though HIV- individuals were older than HIV+ individuals (p= 0.015).
Conclusions: Amyloid deposition is increased in a minority of HIV+ individuals > age 50. Amyloid deposition in HIV+ individuals with symptomatic HAND is increased compared to individuals with asymptomatic HAND or normal cognition in specific regions which could account for cognitive impairment.